This study is looking at how inherited genetic factors, specifically rare pathogenic mutations (RPMs) and genetic risk scores (GRS), relate to finding prostate cancer during a prostate biopsy. Researchers want to see if these genetic assessments can help identify men who are more likely to have prostate cancer detected. You might be able to join if you are a man between 40 and 69 years old, are undergoing a prostate biopsy, and have a PSA (prostate-specific antigen) level between 2.5-10 ng/mL. You also need to be of Caucasian, African American, East Asian, or Latino ethnicity. The main goal is to see if these genetic assessments are linked to a prostate cancer diagnosis from your biopsy report, with results being looked at over 4 years. The current recruitment status is unclear.

Study design

This is an observational study, meaning researchers will observe and collect information without providing specific treatments. It aims to include 1000 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your prostate cancer diagnosis from the biopsy report will be measured at 4 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.